

**Form 51-102F3**  
**Material Change Report**

**1. Name and Address of Company**

BriaCell Therapeutics Corp. ("BriaCell" or the "Company")  
Suite 300 – Bellevue Centre 235 – 15<sup>th</sup> Street  
West Vancouver, BC V7T 2X1

**2. Date of Material Change**

August 25, 2025

**3. News Release**

News releases dated July 31, 2025 regarding the material change referred to in this report were disseminated via GlobeNewswire. Copies of the news releases have been filed on SEDAR+ and are available under the Company's issuer profile at [www.sedarplus.ca](http://www.sedarplus.ca).

**4. Summary of Material Change**

On August 25, 2025, the Company completed a share consolidation of its common shares (the "**Common Shares**") on the basis of one (1) post-consolidation Common Share for every ten (10) pre-consolidation Common Shares (the "**Consolidation**").

**5. Full Description of Material Change**

**5.1 Full Description of Material Change**

No fractional Common Shares were issued in connection with the Consolidation, and each fractional Common Share remaining after the Consolidation that was less than one-half of a Common Share has been cancelled and each fractional Common Share that was at least one-half of a Common Share has been changed to one whole Common Share. The exercise or conversion price and the number of Common Shares issuable under any of the Company's outstanding convertible securities has been proportionately adjusted in connection with the Consolidation.

The Issuer's new CUSIP number is 107930307 and its new ISIN number is CA1079303071. There is no change to the trading symbol.

**5.2 Disclosure for Restructuring Transactions**

Not applicable.

**6. Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**7. Omitted Information**

Not applicable.

**8. Executive Officer**

For further information, please contact:

Gadi Levin, Chief Financial Officer  
Telephone: (888) 485-6340

**9. Date of Report**

August 27, 2025